CrossRefPubMed 12. Steinberg GD, Brendler CB, Squire RA, Isaacs JT: Experimental intravesical therapy for superficial transitional cell OICR-9429 molecular weight carcinoma in a rat bladder tumor model (J). J Urol 1991, 145 (3) : 647–653.PubMed 13. Matsuki T, Watanabe K, Tanaka R: Genus- and species-specific

PCR primers for the detection and identification of bifidobacteria. Curr Issues Intest Microbiol 2003, 4: 61–69.PubMed 14. Haarman M, Knol J: Quantitative real-time PCR assays to identify and quantify fecal Bifidobacterium species in infants receiving a prebiotic infant formula. Appl Environ Microbiol 2005, 71: 2318–2324.CrossRefPubMed 15. Masco L, Huys G, Gevers D, Verbrugghen L, Swings J: Identification of Bifidobacterium species using rep-PCR fingerprinting. Syst Target Selective Inhibitor Library screening Appl Microbiol 2003, 26 (4) : 557–563.CrossRefPubMed 16. Yi C, Huang Y, Guo ZY, Wang SR: Antitumor effect of cytosine deaminase/5-fluorocytosine suicide gene therapy system mediated by Bifidobacterium infantis on melanoma. Acta Pharmacol Sin 2005, 26 (5) : 629–634.CrossRefPubMed 17. Requena T, Burton J, Matsuki T, Munro K, Simon MA, Tanaka R, Watanabe K, Tannock

GW: Identification, detection, and enumeration of human Tipifarnib Bifidobacterium species by PCR targeting the transaldolase gene. Appl Environ Microbiol 2002, 68: 2420–2427.CrossRefPubMed 18. Fujimori M, Amano J, Taniguchi S: The genus Bifidobacterium for cancer gene therapy. Curr Opin Drug Discov Devel 2002, 5 (2) : 200–203.PubMed 19. Satokari R, Grönroos T, Laitinen K, Salminen S, Isolauri E: Bifidobacterium and Lactobacillus DNA in the human placenta. Lett Appl Microbiol 2009, 48 (1) : 8–12.CrossRefPubMed 20. Ventura M, Reniero R, Zink R: Specific identification and targeted characterization of Bifidobacterium lactis from different environmental isolates by a combined multiplex-PCR approach. Appl Environ Microbiol 2001, 67: 2760–2765.CrossRefPubMed 21. Michl P, Gress TM: Bacteria and bacterial toxins as therapeutic

agents for solid tumors. Curr Cancer Drug Targets 2004, 4: 689–702.CrossRefPubMed Competing interests The authors declare that they have no competing Dimethyl sulfoxide interests. Authors’ contributions WT, YH, SZ, YM, GL carried out the experiments described in the study. The Bifidobacterium infantis -mediated TK/GCV suicide gene therapy system is constructed by WT and YH. Bacterial strains and cultivation is finished by SZ and GL. Experimental of rat model finished by YM and WT. Apoptosis and Immunohistochemical is finished by WT and YH. Statistical analysis is finished by WT and YH. All authors read and approved the final manuscript.”
“Background Lewis y antigen is carried by glycoconjugates (glycoproteins and glycolipids) at cell surface.